Following a previous study with diffusion tensor imaging, we investigated the correlation between diffusion-weighted imaging (DWI) and cognitive dysfunction in multiple sclerosis (MS). We studied 60 MS patients (mean age 45.89/9.0 years) using 1.5-T MRI. Disease course was RR/40 and SP/ 20. Mean disease duration was 12.89/8.7 years. Mean EDSS was 3.49/1.7. Whole brain, gray and white matter normalized volumes were calculated on 3D SPGR T1-WI using a fully automated Hybrid SIENAX method. Parenchymal mean diffusivity (PMD) maps were created after automated segmentation of the brain parenchyma and cerebrospinal fluid using T2-WI and DW images. Histogram analysis was performed and DWI indices of peak position (PP), peak height (PH), mean parenc...
Multiple sclerosis (MS) is an inflammatory-demyelinating and neurodegenerative disease of the centra...
Purpose: To report a novel magnetic resonance imaging measure (diffusion orientational complexity [...
Cognitive impairment (CI) occurs in 43 to 70% of multiple sclerosis (MS) patients at both early and ...
Following a previous study with diffusion tensor imaging, we investigated the correlation between di...
Abstract Advanced structural brain imaging techniques, such as diffusion tensor imaging (DTI), have ...
Diffusion-weighted imaging (DWI) has been proposed as a sensitive measure of disease severity capabl...
Diffusion-weighted imaging (DWI) has been proposed as a sensitive measure of disease severity capabl...
Purpose: To report a novel magnetic resonance imaging measure (diffusion orientational complexity [...
Purpose: To report a novel magnetic resonance imaging measure (diffusion orientational complexity [D...
Peak width of skeletonized mean diffusivity (PSMD) is a new MRI marker, which has shown clinical rel...
Peak width of skeletonized mean diffusivity (PSMD) is a new MRI marker, which has shown clinical rel...
Multiple Sclerosis (MS) affects gray matter (GM), usually devoted to executive functions possibly su...
Peak width of skeletonized mean diffusivity (PSMD) is a new MRI marker, which has shown clinical rel...
Background and purpose - Magnetic resonance imaging (MRI) has been explored as a noninvasive tool to...
Peak width of skeletonized mean diffusivity (PSMD) is a new MRI marker, which has shown clinical rel...
Multiple sclerosis (MS) is an inflammatory-demyelinating and neurodegenerative disease of the centra...
Purpose: To report a novel magnetic resonance imaging measure (diffusion orientational complexity [...
Cognitive impairment (CI) occurs in 43 to 70% of multiple sclerosis (MS) patients at both early and ...
Following a previous study with diffusion tensor imaging, we investigated the correlation between di...
Abstract Advanced structural brain imaging techniques, such as diffusion tensor imaging (DTI), have ...
Diffusion-weighted imaging (DWI) has been proposed as a sensitive measure of disease severity capabl...
Diffusion-weighted imaging (DWI) has been proposed as a sensitive measure of disease severity capabl...
Purpose: To report a novel magnetic resonance imaging measure (diffusion orientational complexity [...
Purpose: To report a novel magnetic resonance imaging measure (diffusion orientational complexity [D...
Peak width of skeletonized mean diffusivity (PSMD) is a new MRI marker, which has shown clinical rel...
Peak width of skeletonized mean diffusivity (PSMD) is a new MRI marker, which has shown clinical rel...
Multiple Sclerosis (MS) affects gray matter (GM), usually devoted to executive functions possibly su...
Peak width of skeletonized mean diffusivity (PSMD) is a new MRI marker, which has shown clinical rel...
Background and purpose - Magnetic resonance imaging (MRI) has been explored as a noninvasive tool to...
Peak width of skeletonized mean diffusivity (PSMD) is a new MRI marker, which has shown clinical rel...
Multiple sclerosis (MS) is an inflammatory-demyelinating and neurodegenerative disease of the centra...
Purpose: To report a novel magnetic resonance imaging measure (diffusion orientational complexity [...
Cognitive impairment (CI) occurs in 43 to 70% of multiple sclerosis (MS) patients at both early and ...